ProstaLund AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ProstaLund AB - overview
Location
Lund, -, Sweden
Primary Industry
Medical Devices & Equipment
About
ProstaLund AB is dedicated to advancing medical technology for male urology, focusing on innovative solutions for benign prostatic hyperplasia (BPH) treatment, enhancing patient care through their flagship product, CoreTherm®. ProstaLund AB develops medical technologies specifically for male urology, addressing benign prostatic hyperplasia (BPH). The company has undergone significant changes since its founding, including its acquisition by Farstorps Gard Forvaltnings AB in July 2008. The headquarters is located in Lund, Sweden.
Magnus Bolmsjö serves as the CEO of the company, leading its initiatives in urological innovations. ProstaLund specializes in innovative medical technologies for male urology, particularly targeting benign prostatic hyperplasia (BPH). Its flagship product, CoreTherm®, utilizes a patented individualized heat treatment method to alleviate prostate enlargement symptoms. This minimally invasive procedure offers quick and effective relief for patients suffering from urinary issues.
ProstaLund also provides ancillary products, including treatment and anesthetic catheters used in the CoreTherm® process, thus creating a complete ecosystem for healthcare providers treating BPH patients. In the latest fiscal year of 2022, ProstaLund reported revenue of USD 1. 73 mn, with an EBITDA of USD -1. 06 mn.
The company's revenue model relies on the sale and rental of CoreTherm® machines and the ongoing sale of consumables such as treatment and anesthetic catheters, which ensures a steady stream of income from healthcare institutions utilizing its technology. ProstaLund aims to expand its product offerings and enhance its market reach. The company is currently working on developing new products intended for launch within the next two years, targeting both domestic and international markets. Specific regions for expansion include broader areas of Scandinavia and potential entry into new European markets.
The funding received from the acquisition in July 2008 will be utilized to support these strategic initiatives, enabling further development of innovative solutions in the urology segment.
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Equipment Distributors
Website
www.prostalund.com
Verticals
HealthTech
Company Stage
Acquired
Total Amount Raised
Subscriber access only
ProstaLund AB - timeline of key events
ProstaLund AB - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 2,388,000 | 6,584,000 | 8,614,000 | 9,613,000 | 13,613,000 | 14,612,000 | 13,544,000 | 13,567,000 | 12,886,000 | 12,465,000 | 17,073,000 | - | - | - |
| % Revenue Growth (YoY) | - | 175.7% | 30.8% | 11.6% | 41.6% | 7.3% | (7.3%) | 0.2% | (5.0%) | (3.3%) | 37.0% | - | - | - |
| EBITDA (USD) | (3,558,000) | (829,000) | (4,228,000) | (7,420,000) | (9,059,000) | (11,098,000) | (16,077,000) | (12,566,000) | (10,209,000) | (9,750,000) | (7,547,000) | - | - | - |
| Operating Income (USD) | (3,558,000) | (1,031,000) | (4,587,000) | (7,812,000) | (9,550,000) | (11,809,000) | (16,900,000) | (12,950,000) | (10,438,000) | (9,919,000) | (7,854,000) | - | - | - |
| Operating Margin | (149.0%) | (15.7%) | (53.3%) | (81.3%) | (70.2%) | (80.8%) | (124.8%) | (95.5%) | (81.0%) | (79.6%) | (46.0%) | - | - | - |
| % EBITDA Margin | (149.0%) | (12.6%) | (49.1%) | (77.2%) | (66.5%) | (76.0%) | (118.7%) | (92.6%) | (79.2%) | (78.2%) | (44.2%) | - | - | - |
| NET Income (USD) | (46,030,000) | 66,000 | (4,645,000) | (7,786,000) | (9,373,000) | (11,974,000) | (16,894,000) | (12,950,000) | (10,583,000) | (9,980,000) | (7,884,000) | - | - | - |
| % Net Margin | (1927.6%) | 1.0% | (53.9%) | (81.0%) | (68.9%) | (81.9%) | (124.7%) | (95.5%) | (82.1%) | (80.1%) | (46.2%) | - | - | - |
ProstaLund AB - employee data
ProstaLund AB - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman of the Board | BM | ||||||
| Chairman of the Board | BM | ||||||
| Chairman of the board/board member from Oct. 1 2015 | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.